Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Shareholder Meeting (November 2006)
16 slides from Pyc Therapeutics's shareholder meeting presentation, Nov 29, 2006
Slide 1: Phylogica Annual General Meeting, November 2006
PHYLOGICA ANNUAL GENERAL MEETING, NOVEMBER 2006 AKI VON ROY - CHAIRMAN STEWART WASHER - CHIEF EXECUTIVE OFFICER
Slide 2: Chairman's Address
Chairman’s Address ti ic strategy well progressed, confirming value of ylomer® drug discovery technology — ra -gic partnerships and deals established and mains the gic deals with pharma and biotech partners ttract. major biotech/pharma investment
Slide 3: Chairman's Address cont....
Chairman’s Address cont.... in 2005 at 20¢ now trading at around 30c, reached IPPFoxi imately 80c in May r significant share growth and potential trade sale signi icant Scientific collaborations
Slide 4: Biotech in 2006
Biotech in 2006 maceutical companies are moving towards early e. preclinical deals (median value US$273m per | deal in 2006) i stag peptide drug technology \ ‘purchased by Amgen (NASDAQ: AMGN) September 2006 for Uss38om PHYLOGICA ~
Slide 5: Leading position in next generation drug discovery with Phylomer technology
ng position in-next generation drug discovery with ylomer® technology proven with positive preclinical mpanies will result in more valuable als for Phylogica and potential investment or trade rchase at international values | ;
Slide 6: Drug Development Portfolio
a Drug Develop pment Portfolio YC35B (Burns;
Slide 7: Alliance with Partners
e with Partners Phase II Trials Phase Il Trials “Pha: Phase | Trials End PreClinical Trial —PHYLOGICA A Tite
Slide 8: Potential Projects
Potential Projects anded pipeline of ieee drugs in inflammatory/ i mune diseases and cancer ; rominent biotechnology and ug d covery/development deals with partners who. ve val luable novel disease. targets _
Slide 9: Phylomer discovery deal with Johnson & Johnson
mer® discovery deal with Johnson & Johnson h Pty:Ltd in progress PHYLOGICA ~ ee
Slide 10: Recent Events
RecentEvents ylomei ries expanded 400% resulting i in significant celeration of drug discovery process 3 and European patents granted on core technology
Slide 11: Phylogica
PHYLOGICA :
Slide 12: Phylomer advantages: reduced costs, delivery, royalty stack
d:(reduced costs) delivery potential (patient finaly) io 9 antibody royalty stack (more profits) »:be used for intracellular targets (treat more |
Slide 13: Next generation drug discovery technology - Phylomers
en.drug discovery technology - Phylomers® jor advantages over-other drugs:
Slide 14: Summary cont....
al gy vi mary cont.... ness model focused on early revenue and share International positioning) ith major compa i d with significant upside for - C identified by leading biotech analysts as one of the 10 stock picks
Slide 15: Chief Executive Officer contact
hief Executive Officer. tewartw@phylo ica.com 288 212 PHYLOGICA ~ ee
Slide 16: Annual General Meeting, November 2006
i ANNUAL GENERAL MEETING, NOVEMBER 2006 AKI VON ROY - CHAIRMAN STEWART WASHER - CHIEF EXECUTIVE OFFICER